7 August 2024
Syncona
Limited
("Syncona" or the "Company")
Transaction in Own
Shares
Syncona, a leading life science
investor focused on creating, building and scaling global leaders
in life science announces that, in accordance with the terms of its
share buyback programme announced on 29 September 2023 (the "Share
Buyback Programme"), the Company purchased the following number of
its ordinary shares of no par value ("Ordinary Shares") each
through Deutsche Numis.
|
Date of purchase:
|
6 August
2024
|
|
Aggregate number of Ordinary Shares
purchased:
|
130,000
|
|
Lowest price paid per share
(GBp):
|
116.5962
|
|
Highest price paid per share
(GBp):
|
116.5962
|
|
Volume weighted average price paid
per share (GBp):
|
116.5962
|
The repurchased Ordinary Shares will
be held by the Company in treasury. Following the purchase and
settlement of these Ordinary Shares, the Company's issued ordinary
share capital is 672,214,632 of which 29,129,769 Ordinary Shares
will be held in treasury, which attract no voting rights.
Therefore, the total voting rights in the Company will be
643,084,863. This figure for the total number of voting rights may
be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the FCA's Disclosure Guidance and Transparency Rules.
In accordance with Article 5(1)(b)
of Regulation (EU) No. 596/2014 which forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018, the table
below contains detailed information of the individual trades made
by Deutsche Numis as part of the Share Buyback
Programme.
Individual information:
|
Numbers
of shares purchased
|
Transaction price (pence per share)
|
Time of
transaction
|
Venue
|
|
130,000
|
116.5962
|
16:41.54
|
XLON
|
For further information, please
contact:
Syncona Ltd
Natalie Garland-Collins / Fergus
Witt
Tel: +44 (0) 20 3981 7940
Deutsche Numis
Nathan Brown
Freddie Barnfield
Tel: +44 (0) 20 7260 1000
About
Syncona
Syncona's purpose is to invest to
extend and enhance human life. We do this by creating, building and
scaling companies to deliver transformational treatments to
patients in areas of high unmet need.
We aim to build and maintain a
diversified portfolio of 20-25 globally leading life science
businesses, across development stage, modality and therapeutic
area, for the benefit of all our stakeholders. We focus on
developing treatments that deliver patient impact by working in
close partnership with world-class academic founders and
experienced management teams. Our balance sheet underpins our
strategy, enabling us to take a long-term view as we look to
improve the lives of patients with no or poor treatment options,
build sustainable life science companies and deliver strong
risk-adjusted returns to shareholders.